Tiziana Life Sciences Ltd (TLSA)Healthcare | Biotechnology | London, United Kingdom | NasdaqCM
1.33 USD
+0.10
(8.130%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.31 -0.02 (-0.020%) ⇩ (July 13, 2026, 4:45 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:45 a.m. EDT
The investment case here is a classic 'binary event' play wrapped in a distressed biotech shell. Fundamentally, the company is burning cash with negative free cash flow and a deteriorating balance sheet, offering no safety margin for a traditional value investor. However, the catalysts are compelling: the company is actively dosing patients in Alzheimer's trials and advancing its foralumab program, which has recently triggered analyst price target boosts. The options market confirms this sentiment, with heavy call buying at strikes significantly above the current price, suggesting traders are betting on a successful trial readout or partnership deal to drive the stock higher. The short-term outlook leans positive due to this speculative positioning and upcoming clinical milestones, despite the weak statistical forecast which likely reflects the stock's recent volatility and lack of earnings support. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.106255 |
| AutoARIMA | 0.106255 |
| MSTL | 0.109813 |
| AutoTheta | 0.111206 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.39 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.217 |
| Excess Kurtosis | -1.28 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 876.923 |
| Market Cap | 169,254,640 |
| Forward P/E | -6.66 |
| Beta | 0.44 |
| Previous Name | Tiziana Life Sciences PLC |
| Website | https://www.tizianalifesciences.com |
As of July 11, 2026, 5:45 a.m. EDT: Speculators are overwhelmingly bullish on upside potential, evidenced by significant open interest in out-of-the-money calls at strikes of 2.5 and 5.0, while put activity is virtually non-existent. This creates a highly skewed gamma profile where the market is pricing in a binary event-driven rally rather than a steady grind.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.16891891 |
| Address1 | 14/15 Conduit Street |
| All Time High | 12.17 |
| All Time Low | 0.41 |
| Ask | 1.24 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 183,200 |
| Average Daily Volume3 Month | 211,101 |
| Average Volume | 211,101 |
| Average Volume10Days | 183,200 |
| Beta | 0.443 |
| Bid | 1.17 |
| Bid Size | 1 |
| Book Value | 0.077 |
| City | London |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.33 |
| Current Ratio | 0.763 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.38 |
| Day Low | 1.22 |
| Debt To Equity | 876.923 |
| Display Name | Tiziana Life Sciences |
| Earnings Timestamp End | 1,752,004,800 |
| Earnings Timestamp Start | 1,750,708,800 |
| Ebitda | -21,120,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.42 |
| Enterprise Value | 156,720,848 |
| Eps Current Year | -0.121 |
| Eps Forward | -0.19961944 |
| Eps Trailing Twelve Months | -0.17 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.3098 |
| Fifty Day Average Change | 0.020200014 |
| Fifty Day Average Change Percent | 0.015422212 |
| Fifty Two Week Change Percent | -16.891891 |
| Fifty Two Week High | 2.6 |
| Fifty Two Week High Change | -1.2699999 |
| Fifty Two Week High Change Percent | -0.4884615 |
| Fifty Two Week Low | 1.04 |
| Fifty Two Week Low Change | 0.29000008 |
| Fifty Two Week Low Change Percent | 0.27884623 |
| Fifty Two Week Range | 1.04 - 2.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,542,724,200,000 |
| Float Shares | 63,889,409 |
| Forward Eps | -0.19961944 |
| Forward P E | -6.662678 |
| Free Cashflow | -5,476,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 10 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.47647 |
| Held Percent Institutions | 0.02944 |
| Implied Shares Outstanding | 127,259,131 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,596,153,600 |
| Last Split Factor | 2,499:1000 |
| Long Business Summary | Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom. |
| Long Name | Tiziana Life Sciences Ltd |
| Market | us_market |
| Market Cap | 169,254,640 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_261234197 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -18,431,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 156,528,731 |
| Number Of Analyst Opinions | 1 |
| Open | 1.22 |
| Operating Cashflow | -12,847,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 44 20 7495 2379 |
| Post Market Change | -0.0200001 |
| Post Market Change Percent | -1.5037669 |
| Post Market Price | 1.31 |
| Post Market Time | 1,783,975,513 |
| Prev Name | Tiziana Life Sciences PLC |
| Previous Close | 1.23 |
| Price Eps Current Year | -10.991736 |
| Price Hint | 4 |
| Price To Book | 17.272728 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.722 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.1 |
| Regular Market Change Percent | 8.13008 |
| Regular Market Day High | 1.38 |
| Regular Market Day Low | 1.22 |
| Regular Market Day Range | 1.22 - 1.38 |
| Regular Market Open | 1.22 |
| Regular Market Previous Close | 1.23 |
| Regular Market Price | 1.33 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 384,306 |
| Return On Assets | -1.1596199 |
| Return On Equity | -9.24323 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 127,259,131 |
| Shares Percent Shares Out | 0.0123000005 |
| Shares Short | 1,565,672 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,460,023 |
| Short Name | Tiziana Life Sciences Ltd |
| Short Percent Of Float | 0.0431 |
| Short Ratio | 7.63 |
| Source Interval | 15 |
| Symbol | TLSA |
| Target High Price | 9.093458 |
| Target Low Price | 9.093458 |
| Target Mean Price | 9.093458 |
| Target Median Price | 9.093458 |
| Total Cash | 4,010,000 |
| Total Cash Per Share | 0.033 |
| Total Debt | 456,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.17 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.5137 |
| Two Hundred Day Average Change | -0.18369997 |
| Two Hundred Day Average Change Percent | -0.12135824 |
| Type Disp | Equity |
| Volume | 384,306 |
| Website | https://www.tizianalifesciences.com |
| Zip | W1S 2XJ |